The Intestinal Microbiota Modulates the Anticancer Immune Effects of Cyclophosphamide
Open accessThe DOI matches its Crossref record; 42 of the 43 references it cites were found in a registry or an index.
Abstract
The Microbiota Makes for Good Therapy: The gut microbiota has been implicated in the development of some cancers, such as colorectal cancer, but—given the important role our intestinal habitants play in metabolism—they may also modulate the efficacy of certain cancer therapeutics. Iida et al. (p. 967 ) evaluated the impact of the microbiota on the efficacy of an immunotherapy [CpG (the cytosine, guanosine, phosphodiester link) oligonucleotides] and oxaliplatin, a platinum compound used as a chemotherapeutic. Both therapies were reduced in efficacy in tumor-bearing mice that lacked microbiota, with the microbiota important for activating the innate immune response against the tumors. Viaud et al. (p. 971 ) found a similar effect of the microbiota on tumor-bearing mice treated with cyclophosphamide, but in this case it appeared that the microbiota promoted an adaptive immune response against the tumors.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“and that therapeutic responses may be improved via its modulation (13, 14)”
From Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients (2018) · cites this paper as [14]
In the citing paper
“The P-ESC was considered representative of baseline microbiome data due to observations that the microbiome of patients treated with anti-PD-1, unlike anti-CTLA-4 or chemotherapy, is stable early after therapy initiation17–19.”
From Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1 (2022) · cites this paper as [19]
In the citing paper
“In mouse models, certain gut commensals mediate efficacy of anticancer therapies, including chemotherapy, radiotherapy, and immunotherapies such as adoptive T cell transfer, intratumoral CpG-oligonucleotides, and ICIs.”
From Melanoma and microbiota: Current understanding and future directions (2024) · cites this paper as [3]
In the citing paper
“In addition, broad-spectrum antibiotics (mainly beta-lactams) taken prior to immunotherapy markedly reduce the clinical benefit of ICIs, chimeric antigen receptor (CAR)-T cells, stem cell transplantation in patients, and immunogenic chemotherapy in preclinical tumor models.”
From Melanoma and microbiota: Current understanding and future directions (2024) · cites this paper as [3]
In the citing paper
“The gut microbiome has been shown to have multiple effects on tumor biology, such as the transformation process, tumor progression, and the response to anticancer therapies including immunotherapy (21-29).”
From The human tumor microbiome is composed of tumor type–specific intracellular bacteria (2020) · cites this paper as [26]
14 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
QIIME allows analysis of high-throughput community sequencing data
Caporaso, J. G., Kuczynski, J., Stombaugh, J., Bittinger, K., Bushman, F. D., Costello, E. K., Fierer, N., Peña, A. G., Goodrich, J. K., Gordon, J. I., et al. (2010) · Nature Methods · doi:10.1038/nmeth.f.303 · Cited by 34,887
Cd-hit: a fast program for clustering and comparing large sets of protein or nucleotide sequences
Li, W., & Godzik, A. (2006) · Bioinformatics · doi:10.1093/bioinformatics/btl158 · Cited by 11,410
The Ribosomal Database Project: improved alignments and new tools for rRNA analysis
Cole, J. R., Wang, Q., Cardenas, E., Fish, J., Chai, B., Farris, R. J., Kulam-Syed-Mohideen, A. S., McGarrell, D. M., Marsh, T., Garrity, G. M., et al. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkn879 · Cited by 4,762
Interactions Between the Microbiota and the Immune System
Hooper, L. V., Littman, D. R., & Macpherson, A. J. (2012) · Science · doi:10.1126/science.1223490 · Cited by 4,173 · cited 2×
“Finally, monoassociation of tumor-bearing GF mice with SFB, which promotes Th17 cell differentiation in the LP (1, 13, 14) also had a detrimental impact on the tumor growthinhibitory effect of CTX (Fig.”
BackgroundImmunogenic Cell Death in Cancer Therapy
Kroemer, G., Galluzzi, L., Kepp, O., & Zitvogel, L. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-100008 · Cited by 3,303 · cited 1×
“Some antineoplastic agents mediate part of their anticancer activity by stimulating anticancer immune responses (6).”
BackgroundSelf-citationApetoh, L., Ghiringhelli, F., Tesniere, A., Obeid, M., Ortiz, C., Criollo, A., Mignot, G., Maiuri, M. C., Ullrich, E., Saulnier, P., et al. (2007) · Nature Medicine · doi:10.1038/nm1622 · Cited by 3,056 · cited 1×
“S6A) and is required for the therapeutic success of anticancer chemotherapies in several tumor models (19).”
BackgroundSelf-citationInnate immunity and intestinal microbiota in the development of Type 1 diabetes
Wen, L., Ley, R. E., Volchkov, P. Y., Stranges, P. B., Avanesyan, L., Stonebraker, A. C., Hu, C., Wong, F. S., Szot, G. L., Bluestone, J. A., et al. (2008) · Nature · doi:10.1038/nature07336 · Cited by 1,921
Wu, S., Rhee, K.-J., Albesiano, E., Rabizadeh, S., Wu, X., Yen, H.-R., Huso, D. L., Brancati, F. L., Wick, E., McAllister, F., et al. (2009) · Nature Medicine · doi:10.1038/nm.2015 · Cited by 1,812
Gut-Residing Segmented Filamentous Bacteria Drive Autoimmune Arthritis via T Helper 17 Cells
Wu, H.-J., Ivanov, I. I., Darce, J., Hattori, K., Shima, T., Umesaki, Y., Littman, D. R., Benoist, C., & Mathis, D. (2010) · Immunity · doi:10.1016/j.immuni.2010.06.001 · Cited by 1,577
Generation of pathogenic TH17 cells in the absence of TGF-β signalling
Ghoreschi, K., Laurence, A., Yang, X.-P., Tato, C. M., McGeachy, M. J., Konkel, J. E., Ramos, H. L., Wei, L., Davidson, T. S., Bouladoux, N., et al. (2010) · Nature · doi:10.1038/nature09447 · Cited by 1,388
Self-citation
Research works printed but not linked: 1
- 10.1073/pnas.1113744109 · DOI · Paper page
Cited by
Items 301–400 of 1,012
The gut microbiota in cancer immunity and immunotherapy
Xie, M., Li, X., Lau, H. C.-H., & Yu, J. (2025) · Cellular and Molecular Immunology · doi:10.1038/s41423-025-01326-2 · Cited by 138
Choi, Y., Lichterman, J. N., Coughlin, L. A., Poulides, N., Li, W., Del Valle, P., Palmer, S. N., Gan, S., Kim, J., Zhan, X., et al. (2023) · Science Immunology · doi:10.1126/sciimmunol.abo2003 · Cited by 132
“…highlighted the importance of gut bacteria translocation into secondary lymphoid organs for optimal cyclophosphamide immune-mediated anti-cancer responses, identifying a novel mechanism by which this commonly used alkylating chemotherapeutic agent induces host immune anti-cancer effects (24, 72).”
Deep sequencing reveals microbiota dysbiosis of tongue coat in patients with liver carcinoma
Lu, H., Ren, Z., Li, A., Zhang, H., Jiang, J., Xu, S., Luo, Q., Zhou, K., Sun, X., Zheng, S., et al. (2016) · Scientific Reports · doi:10.1038/srep33142 · Cited by 139
Sadrekarimi, H., Gardanova, Z. R., Bakhshesh, M., Ebrahimzadeh, F., Yaseri, A. F., Thangavelu, L. P., Hasanpoor, Z., Zadeh, F. A., & Kahrizi, M. S. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03492-7 · Cited by 142
Chemokines, cytokines and exosomes help tumors to shape inflammatory microenvironment
Атретханы, К.-С. Н., Drutskaya, M. S., Nedospasov, S. A., Grivennikov, S. I., & Kuprash, D. V. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.09.011 · Cited by 138
Mechanisms and consequences of gut commensal translocation in chronic diseases
Fine, R. L., Vieira, S. M., Gilmore, M. S., & Kriegel, M. A. (2019) · Gut Microbes · doi:10.1080/19490976.2019.1629236 · Cited by 136
The power of small changes: Comprehensive analyses of microbial dysbiosis in breast cancer
Parida, S., & Sharma, D. (2019) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2019.04.001 · Cited by 116
Host and gut bacteria share metabolic pathways for anti-cancer drug metabolism
Spanogiannopoulos, P., Kyaw, T. S., Guthrie, B. G. H., Bradley, P. H., Lee, J. V., Melamed, J., Malig, Y. N. A., Lam, K. N., Gempis, D., Sandy, M., et al. (2022) · Nature Microbiology · doi:10.1038/s41564-022-01226-5 · Cited by 132
The gut microbiome and cancer: from tumorigenesis to therapy
Nobels, A., van Marcke, C., Jordan, B. F., Hul, M. V., & Cani, P. D. (2025) · Nature Metabolism · doi:10.1038/s42255-025-01287-w · Cited by 136
Yang, K., Hou, Y., Zhang, Y., Liang, H., Sharma, A., Zheng, W., Wang, L., Torres, R., Tatebe, K., Chmura, S. J., et al. (2021) · Journal of Experimental Medicine · doi:10.1084/jem.20201915 · Cited by 124
Costa, D. A., Nobre, J. G., Batista, M. V., Ribeiro, C., Callé, C., Cortés, A., Marhold, M., Negreiros, I., Borralho, P., Brito, M., et al. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.584332 · Cited by 140
Pflug, N., Kluth, S., Vehreschild, J. J., Bahlo, J., Tacke, D., Biehl, L., Eichhorst, B., Fischer, K., Cramer, P., Fink, A.-M., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1150399 · Cited by 123
Beyond the tumour microenvironment
Laplane, L., Duluc, D., Bikfalvi, A., Larmonier, N., & Pradeu, T. (2019) · International Journal of Cancer · doi:10.1002/ijc.32343 · Cited by 152
Alterations of fecal bacterial communities in patients with lung cancer.
Zhang, W., Zhao, S., Luo, J., Dong, X., Hao, Y., Li, H., Shan, L., Zhou, Y., Shi, H., Zhang, Z.-Y., et al. (2018) · Europe PMC (PubMed Central) · Cited by 141
Roles of mitochondria in the hallmarks of metastasis
Scheid, A. D., Beadnell, T. C., & Welch, D. R. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-01125-8 · Cited by 137
Gut bacteria require neutrophils to promote mammary tumorigenesis
Lakritz, J. R., Poutahidis, T., Mirabal, S., Varian, B. J., Levkovich, T., Ibrahim, Y. M., Ward, J. M., Teng, E. C., Fisher, B., Parry, N., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3328 · Cited by 119
Li, H., Huang, S., Zhou, D.-D., Xiong, R.-G., Luo, M., Saimaiti, A., Han, M.-K., Gan, R., Zhu, H., & Li, H. (2023) · Journal of Advanced Research · doi:10.1016/j.jare.2023.01.008 · Cited by 132
Intestinal Microbiota: A Novel Target to Improve Anti-Tumor Treatment?
Villéger, R., Lopès, A., Carrier, G., Veziant, J., Billard, E., Barnich, N., Gagnière, J., Vazeille, E., & Bonnet, M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20184584 · Cited by 119
The cancer-immune dialogue in the context of stress
Ma, Y., & Kroemer, G. (2023) · Nature reviews. Immunology · doi:10.1038/s41577-023-00949-8 · Cited by 131
Self-citationFine-Tuning Cancer Immunotherapy: Optimizing the Gut Microbiome
Pitt, J. M., Vétizou, M., Waldschmitt, N., Kroemer, G., Chamaillard, M., Boneca, I. G., & Zitvogel, L. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0448 · Cited by 117
Self-citationArmstrong, H., Bording-Jorgensen, M., Dijk, S., & Wine, E. (2018) · Cancers · doi:10.3390/cancers10030083 · Cited by 118
Gut Microbiome: A Promising Biomarker for Immunotherapy in Colorectal Cancer
Temraz, S. N., Nassar, F. J., Nasr, R., Charafeddine, M., Mukherji, D., & Shamseddine, A. I. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20174155 · Cited by 132
Gut Microbiome and Response to Cardiovascular Drugs
Tuteja, S., & Ferguson, J. F. (2019) · Circulation Genomic and Precision Medicine · doi:10.1161/circgen.119.002314 · Cited by 133
Malesci, A., Bianchi, P., Celesti, G., Basso, G., Marchesi, F., Grizzi, F., Di Caro, G., Cavalleri, T., Rimassa, L., Palmqvist, R., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1342918 · Cited by 124
Towards a mechanistic understanding of reciprocal drug–microbiome interactions
Zimmermann, M., Patil, K. R., Typas, A., & Maier, L. (2021) · Molecular Systems Biology · doi:10.15252/msb.202010116 · Cited by 121
Gut microbiome and anticancer immune response: really hot Sh*t!
Viaud, S., Daillère, R., Boneca, I. G., Lepage, P., Langella, P., Chamaillard, M., Pittet, M. J., Ghiringhelli, F., Trinchieri, G., Goldszmid, R., et al. (2015) · Cell Death & Differentiation · doi:10.1038/cdd.2014.56 · Cited by 123
Self-citationMicrobiota in cancer development and treatment
Raza, M. H., Gul, K., Arshad, A., Riaz, N., Waheed, U., Rauf, A., Aldakheel, F. M., Alduraywish, S. A., Rehman, M. U., Abdullah, M., et al. (2018) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-018-2816-0 · Cited by 129
Teoh, F., & Pavelka, N. (2016) · Pathogens · doi:10.3390/pathogens5010006 · Cited by 110
Insights Into Lung Cancer Immune-Based Biology, Prevention, and Treatment
Saab, S., Zalzale, H., Rahal, Z., Khalifeh, Y., Sinjab, A. F., & Kadara, H. N. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00159 · Cited by 131
Understanding and Managing Sepsis in Patients With Cancer in the Era of Antimicrobial Resistance
Gudiol, C., Albasanz‐Puig, A., Cuervo, G., & Carratalà, J. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.636547 · Cited by 132
Huang, J., Huang, J., Li, Y., Wang, Y., Wang, F., Qiu, X., Liu, X., & Li, H. (2021) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.1c02294 · Cited by 122
Sporadic colorectal cancer: microbial contributors to disease prevention, development and therapy
Drewes, J. L., Housseau, F., & Sears, C. L. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.189 · Cited by 121
Role of Gut Microbiota in the Development and Treatment of Colorectal Cancer
Lin, C., Cai, X., Zhang, J., Wang, W., Sheng, Q., Hua, H., & Zhou, X. (2018) · Digestion · doi:10.1159/000494052 · Cited by 121
Chamseddine, A. N., Ducreux, M. P., Armand, J., Paolettí, X., Satar, T., Paci, A., & Mir, O. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.03.002 · Cited by 124
Sepsis and Cancer: An Interplay of Friends and Foes
Mirouse, A., Vigneron, C., Llitjos, J., Chiche, J., Mira, J. P., Mokart, D., Azoulay, É., & Pène, F. (2020) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202004-1116tr · Cited by 130
Sun, J., Chen, F., & Wu, G. (2023) · The ISME Journal · doi:10.1038/s41396-023-01483-0 · Cited by 126
Tao, J., Li, S., Gan, R.-Y., Zhao, C.-N., Meng, X., & Li, H.-B. (2020) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2018.1555789 · Cited by 119
Rajpoot, M., Sharma, A. K., Sharma, A. K., & Gupta, G. K. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.02.003 · Cited by 123
Masters, G. A., Krilov, L., Bailey, H. H., Brose, M. S., Burstein, H. J., Diller, L., Dizon, D. S., Fine, H. A., Kalemkerian, G. P., Moasser, M. M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.9746 · Cited by 137
Barnestein, R., Galland, L., Kalfeist, L., Ghiringhelli, F., Ladoire, S., & Limagne, E. (2022) · OncoImmunology · doi:10.1080/2162402x.2022.2120676 · Cited by 124
Self-citationDC-Derived Exosomes for Cancer Immunotherapy
Yao, Y., Fu, C., Zhou, L., Mi, Q., & Jiang, A. (2021) · Cancers · doi:10.3390/cancers13153667 · Cited by 121
Gut microbiota and immunity relevance in eubiosis and dysbiosis
Al-Rashidi, H. E. (2022) · Saudi Journal of Biological Sciences · doi:10.1016/j.sjbs.2021.10.068 · Cited by 105
European Groundshot—addressing Europe's cancer research challenges: a Lancet Oncology Commission
Lawler, M., Davies, L., Oberst, S., Oliver, K. R., Eggermont, A. M. M., Schmutz, A., Vecchia, C. L., Allemani, C., Lievens, Y. N., Naredi, P. L. J., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(22)00540-x · Cited by 130
Lee, J.-C., Lee, H.-Y., Kim, T. K., Kim, M., Park, Y. M., Kim, J., Park, K., Kweon, M., Kim, S., Bae, J., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0187515 · Cited by 123
The Potential of the Gut Microbiome to Reshape the Cancer Therapy Paradigm: A Review
Liu, L., & Shah, K. (2022) · JAMA Oncology · doi:10.1001/jamaoncol.2022.0494 · Cited by 111
Antibiotic therapy and outcome from immune-checkpoint inhibitors
Pinato, D. J., Gramenitskaya, D., Altmann, D. M., Boyton, R. J., Mullish, B. H., Marchesi, J. R., & Bower, M. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0775-x · Cited by 116
Fu, Y., Feng, B., Zhu, Z., Feng, X., Chen, S.-F., Li, L., Yin, Z., Huang, C., Chen, X., Zhang, B., et al. (2018) · Molecules · doi:10.3390/molecules23071801 · Cited by 120
Dong, M., Meng, Z., Kuerban, K., Qi, F., Liu, J., Wei, Y., Wang, Q., Jiang, S., Feng, M., & Ye, L. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-1099-3 · Cited by 119
Chen, D., Chen, G., Ding, Y., Wan, P., Peng, Y., Chen, C., Ye, H., Zeng, X., & Ran, L. (2019) · Journal of Functional Foods · doi:10.1016/j.jff.2019.103470 · Cited by 117
Pharmacomicrobiomics in inflammatory arthritis: gut microbiome as modulator of therapeutic response
Scher, J. U., Nayak, R. R., Úbeda, C., Turnbaugh, P. J., & Abramson, S. B. (2020) · Nature Reviews Rheumatology · doi:10.1038/s41584-020-0395-3 · Cited by 121
Nuytens, F., Dabakuyo‐Yonli, T. S., Meunier, B., Gagnière, J., Collet, D., D’Journo, X. B., Brigand, C., Perniceni, T., Carrère, N., Mabrut, J., et al. (2021) · JAMA Surgery · doi:10.1001/jamasurg.2020.7081 · Cited by 116
Gut Microbiome as a Potential Factor for Modulating Resistance to Cancer Immunotherapy
Shui, L., Yang, X., Li, J., Yi, C., Sun, Q., & Zhu, H. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02989 · Cited by 115
Microbiota dysbiosis: a new piece in the understanding of the carcinogenesis puzzle
García-Castillo, V., Sanhueza, E., McNerney, E. M., Oñate, S. A., & García, A. (2016) · Journal of Medical Microbiology · doi:10.1099/jmm.0.000371 · Cited by 125
The Gut-liver Axis in Immune Remodeling: New insight into Liver Diseases
Yang, X., Lu, D., Zhuo, J., Lin, Z., Yang, M., & Xu, X. (2020) · International Journal of Biological Sciences · doi:10.7150/ijbs.46405 · Cited by 119
Guipaud, O., Jaillet, C., Clément-Colmou, K., François, A., Supiot, S., & Milliat, F. (2018) · British Journal of Radiology · doi:10.1259/bjr.20170762 · Cited by 121
The significance of microbiome in personalized medicine
Behrouzi, A., Nafari, A. H., & Siadat, S. D. (2019) · Clinical and Translational Medicine · doi:10.1186/s40169-019-0232-y · Cited by 120
Understanding human health through metatranscriptomics
Ojala, T., Kankuri, E. M., & Kankainen, M. (2023) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2023.02.002 · Cited by 120
Introducing the Microbiome into Precision Medicine
Kuntz, T. M., & Gilbert, J. A. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2016.10.001 · Cited by 101
Gut microbiota-mediated immunomodulation in tumor
Liu, X., Chen, Y., Zhang, S., & Dong, L. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-01983-x · Cited by 112
Th17 cells and Tregs: unlikely allies
Chen, X., & Oppenheim, J. J. (2014) · Journal of Leukocyte Biology · doi:10.1189/jlb.1213633 · Cited by 121
Cancer Immunotherapy: A Focus on the Regulation of Immune Checkpoints
Shi, T., Ma, Y., Yu, L., Jiang, J., Shen, S., Hou, Y., & Wang, T. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19051389 · Cited by 115
The Microbiome and Cancer: Is the ‘Oncobiome’ Mirage Real?
Thomas, R. M., & Jobin, C. (2015) · Trends in Cancer · doi:10.1016/j.trecan.2015.07.005 · Cited by 110
Antibiotic Use Does Not Appear to Influence Response to Nivolumab
(2017) · Anticancer Research · doi:10.21873/anticanres.11680 · Cited by 107
Self-citationXu, H., Cao, C., Ren, Y., Weng, S., Liu, L., Guo, C., Wang, L., Han, X., Ren, J., & Liu, Z. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.949490 · Cited by 126
Pröbstel, A.-K., & Baranzini, S. E. (2018) · Neurotherapeutics · doi:10.1007/s13311-017-0587-y · Cited by 110
Metabolite and Microbiome Interplay in Cancer Immunotherapy
Johnson, C. H., Spilker, M. E., Goetz, L. H., Peterson, S. N., & Siuzdak, G. E. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0309 · Cited by 113
Ševčíková, A., Izoldova, N., Števurková, V., Kasperova, B., Chovanec, M., Čierniková, S., & Mego, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23010488 · Cited by 112
Gut Microbiome in Colorectal Cancer: Clinical Diagnosis and Treatment
Liu, Y., Lau, H. C.-H., Cheng, W. Y., & Yu, J. Q. (2022) · Genomics Proteomics & Bioinformatics · doi:10.1016/j.gpb.2022.07.002 · Cited by 119
Glioma and temozolomide induced alterations in gut microbiome
Patrizz, A., Dono, A., Zorofchian, S., Hines, G., Takayasu, T., Husein, N., Otani, Y., Arevalo, O., Choi, H. A., Savarraj, J. P. J., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-77919-w · Cited by 114
Che, Y., Chen, G., Guo, Q., Duan, Y., Feng, H., & Xia, Q. (2023) · Hepatology · doi:10.1097/hep.0000000000000047 · Cited by 108
Role of Akkermansia in Human Diseases: From Causation to Therapeutic Properties
Pellegrino, A., Coppola, G., Santopaolo, F., Gasbarrini, A., & Ponziani, F. R. (2023) · Nutrients · doi:10.3390/nu15081815 · Cited by 112
Shi, L., Sheng, J., Wang, M., Luo, H., Zhu, J., Zhang, B., Liu, Z., & Yang, X. (2019) · Theranostics · doi:10.7150/thno.35131 · Cited by 101
Pharmacomicrobiomics: Influence of gut microbiota on drug and xenobiotic metabolism
Dikeocha, I. J., Al‐Kabsi, A. M., Miftahussurur, M., & Alshawsh, M. A. (2022) · The FASEB Journal · doi:10.1096/fj.202101986r · Cited by 114
Yamazaki, T., Pitt, J. M., Vétizou, M., Marabelle, A., Flores, C., Rekdal, Ø., Kroemer, G., & Zitvogel, L. (2016) · Cell Death and Differentiation · doi:10.1038/cdd.2016.35 · Cited by 109
Self-citationDietary nutrition and gut microflora: A promising target for treating diseases
Nie, Y., Luo, F., & Lin, Q. (2018) · Trends in Food Science & Technology · doi:10.1016/j.tifs.2018.03.002 · Cited by 111
Huyghe, N. D., Baldin, P., & den Eynde, M. V. (2019) · Gastroenterology report · doi:10.1093/gastro/goz061 · Cited by 114
Limitations and opportunities for immune checkpoint inhibitors in pediatric malignancies
Park, J. A., & Cheung, N.-K. V. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.05.006 · Cited by 103
Gut microbiota shifts in patients with gastric cancer in perioperative period
Liang, W., Yang, Y., Wang, H., Wang, H., Yu, X., Lu, Y., Shen, S., & Teng, L. (2019) · Medicine · doi:10.1097/md.0000000000016626 · Cited by 115
Unlocking the Potential of the Human Microbiome for Identifying Disease Diagnostic Biomarkers
Hajjo, R., Sabbah, D. A., & Bawab, A. Q. A. (2022) · Diagnostics · doi:10.3390/diagnostics12071742 · Cited by 116
Sethi, V., Vitiello, G. A., Saxena, D., Miller, G., & Dudeja, V. (2019) · Gastroenterology · doi:10.1053/j.gastro.2018.12.045 · Cited by 104
Fecal Microbial Transplantation for Diseases Beyond Recurrent Clostridium Difficile Infection
D’Haens, G. R., & Jobin, C. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.04.053 · Cited by 98
Microbes and Cancer: Friends or Faux?
Azevedo, M. M., Pina‐Vaz, C., & Baltazar, F. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093115 · Cited by 104
Immunotherapy in Prostate Cancer
Fay, E. K., & Graff, J. N. (2020) · Cancers · doi:10.3390/cancers12071752 · Cited by 111
Probiotics and immunity: provisional role for personalized diets and disease prevention
Bubnov, R. V., Spivak, M. Y., Lazarenko, L. M., Bomba, A., & Boyko, N. (2015) · The EPMA Journal · doi:10.1186/s13167-015-0036-0 · Cited by 112
Clinical applications of gut microbiota in cancer biology
Wong, S. H., Kwong, T. N. Y., Wu, C.-Y., & Yu, J. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.05.003 · Cited by 100
Pingili, A. K., Chaib, M., Sipe, L. M., Miller, E. J., Teng, B., Sharma, R., Yarbro, J. R., Asemota, S., Abdallah, Q. A., Mims, T. S., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109285 · Cited by 104
Butyrate production from high-fiber diet protects against lymphoma tumor
Wei, W., Sun, W., Yu, S., Yang, Y., & Ai, L. (2016) · Leukemia & Lymphoma · doi:10.3109/10428194.2016.1144879 · Cited by 102
“The antitumour efficacy of cyclophosphamide could be partially restored by the adoptive transfer of IFNgIL-17 T cells.[11] Butyrate, a short chain fatty acid (SCFA) produced by bacterial fermentation of dietary fibers in the colon, serves as the primary source of energy for colonocytes.”
BackgroundProbiotics in the Treatment of Colorectal Cancer
Hendler, R., & Zhang, Y. (2018) · Medicines · doi:10.3390/medicines5030101 · Cited by 142
Gut microbial dysbiosis associates hepatocellular carcinoma via the gut-liver axis
Jiang, J., Chen, X., Ren, Z., & Zheng, S. (2018) · Hepatobiliary & pancreatic diseases international · doi:10.1016/j.hbpd.2018.11.002 · Cited by 107
Elkrief, A., Pidgeon, R., Vareki, S. M., Messaoudene, M., Castagner, B., & Routy, B. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01211-7 · Cited by 108
Wang, C., Yang, S., Gao, L., Wang, L., & Cao, L. (2018) · Food & Function · doi:10.1039/c7fo01886j · Cited by 105
Gut Microbiota and Colorectal Cancer Development: A Closer Look to the Adenoma-Carcinoma Sequence
Vacante, M., Ciuni, R., Basile, F., & Biondi, A. (2020) · Biomedicines · doi:10.3390/biomedicines8110489 · Cited by 106
Crosstalk between gut microbiota and host immune system and its response to traumatic injury
Ullah, H., Arbab, S., Tian, Y., Chen, Y., Liu, C., Li, Q., & Li, K. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1413485 · Cited by 111
From the Bottom-Up: Chemotherapy and Gut-Brain Axis Dysregulation
Bajic, J. E., Johnston, I. N., Howarth, G. S., & Hutchinson, M. R. (2018) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2018.00104 · Cited by 100
Effect of Antibiotic Use on Outcomes with Systemic Therapies in Metastatic Renal Cell Carcinoma
Lalani, A.-K. A., Xie, W., Braun, D. A., Kaymakcalan, M., Bossé, D., Steinharter, J. A., Martini, D. J., Simantov, R., Lin, X., Wei, X. X., et al. (2020) · European Urology Oncology · doi:10.1016/j.euo.2019.09.001 · Cited by 100
TLR Signaling Modulates Side Effects of Anticancer Therapy in the Small Intestine
Frank, M., Hennenberg, E. M., Eyking, A., Rünzi, M., Gerken, G., Scott, P., Parkhill, J., Walker, A. W., & Cario, E. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1402481 · Cited by 97
Microbiota—myeloid cell crosstalk beyond the gut
Gorjifard, S., & Goldszmid, R. S. (2016) · Journal of Leukocyte Biology · doi:10.1189/jlb.3ri0516-222r · Cited by 96
Keung, E. Z.-Y., Lazar, A. J., Torres, K. E., Wang, W.-L., Cormier, J. N., Guadagnolo, B. A., Bishop, A. J., Lin, H. Y., Hunt, K. K., Bird, J. E., et al. (2018) · BMC Cancer · doi:10.1186/s12885-018-4829-0 · Cited by 101
Su, J., Li, D., Chen, Q., Li, M., Su, L., Luo, T. L., Liang, D., Lai, G., Shuai, O., Jiao, C., et al. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.03099 · Cited by 108
The Gut–Brain Axis, Paving the Way to Brain Cancer
Mehrian‐Shai, R., Reichardt, J. K. V., Harris, C. C., & Toren, A. (2019) · Trends in cancer · doi:10.1016/j.trecan.2019.02.008 · Cited by 103
Metadata
- Authors
- Viaud, S., Saccheri, F., Mignot, G., Yamazaki, T., Daillère, R., Hannani, D., Enot, D. P., Pfirschke, C., Engblom, C., Pittet, M. J., Schlitzer, A., Ginhoux, F., Apetoh, L., Chachaty, E., Woerther, P.-L., Eberl, G., Bérard, M., Ecobichon, C., Clermont, D., Bizet, C., Gaboriau-Routhiau, V., Cerf-Bensussan, N., Opolon, P., Yessaad, N., Vivier, E., Ryffel, B., Elson, C. O., Doré, J., Kroemer, G., Lepage, P., Boneca, I. G., Ghiringhelli, F., & Zitvogel, L.
- Affiliations
- Université Paris-Sud (FR)
- Inserm (FR)
- Harvard University (US)
- Center for Systems Biology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
- Agency for Science, Technology and Research (SG)
- Institut National de la Santé et de la Recherche Médicale, U866, Centre Georges François Leclerc, Dijon, France.
- Service de Microbiologie, Institut Gustave Roussy, Villejuif, France.
- Institut Gustave Roussy (FR)
- Institut Pasteur (FR)
- Nimalerie Centrale, Institut Pasteur, Paris, France.
- Institut National de la Recherche Agronomique, Micalis–UMR1319, 78350 Jouy-en-Josas, France.
- Centre National de la Recherche Scientifique (FR)
- Centre d’Immunologie de Marseille-Luminy, Aix-Marseille Université UM2, Marseille, France.
- Université d'Orléans (FR)
- University of Alabama at Birmingham (US)
- AgroParisTech (FR)
- Corresponding author
- Ghiringhelli, François
- Zitvogel, Laurence
- ORCID
- Mignot, Grégoire
- Yamazaki, Takahiro
- Daillère, Romain
- Hannani, Dalil
- Pfirschke, Christina
- Engblom, Camilla
- Schlitzer, Andreas
- Ginhoux, Florent
- Woerther, Paul-Louis
- Eberl, Gérard
- Clermont, Dominique
- Opolon, Paule
- Ryffel, Bernhard
- Elson, Charles O.
- Kroemer, Guido
- Lepage, Patricia
- Boneca, Ivo Gomperts
- Ghiringhelli, François
- Zitvogel, Laurence
- Venue
- Science
- Published
- 2013-11-22
- Volume
- 342
- Issue
- 6161
- Pages
- 971-976
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC4048947
- OpenAlex
- W2059128083
- Cited by
- 2,050
- References
- 43
- Citations by year
- 2026: 109 · 2025: 165 · 2024: 176 · 2023: 216 · 2022: 234 · 2021: 217 · 2020: 220 · 2019: 183 · 2018: 137 · 2017: 116 · 2016: 98 · 2015: 101 · 2014: 69 · 2013: 6
- FWCI
- 40.94
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Archive ouverte UNIGE (University of Geneva) (acceptedVersion, other-oa)
- HAL AMU (submittedVersion)
- Funders
- Agence Nationale de la Recherche (ANR-10-LABX-0015, ANR-11-PHUC-0002)
- National Cancer Institute (P50CA086355)
- National Institute of Allergy and Infectious Diseases (R01AI084880)
- National Institute of Diabetes and Digestive and Kidney Diseases (P01DK071176)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- cyclophosphamide, gut microbiota, antitumor immunity, Gram-positive bacteria, Th17 cells, memory T cells, secondary lymphoid organs, bacterial translocation, germ-free mice, antibiotic therapy, adoptive transfer, small intestine
- MeSH terms
- Animals, Anti-Bacterial Agents, Antineoplastic Agents, Cyclophosphamide, Germ-Free Life, Gram-Positive Bacteria, Immunologic Memory, Immunosuppressive Agents, Intestine, Small, Lymphoid Tissue, Neoplasms, Bacterial Translocation, Adoptive Transfer, Mice, Th17 Cells, Microbiota
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.